Cardiac Functional and Structural Implications of Lamin A/C Mutations

 描述（由申请方提供）：心肌病和心律失常是发病率高且治疗有限的疾病。虽然已经发现了大量的基因有助于这些疾病的病因，转化研究-遗传知识的实际应用，以改善受影响的个人和他们的家庭的筛查，诊断和治疗-一直是有限的。一个主要的障碍是缺乏功能研究，以了解基因型和新兴的表型之间的关系，在多个生理尺度（细胞组织），并确定因素，导致临床变异之间和家庭内。这项研究的重点是三个受影响的家庭，每个家庭都有不同的核纤层蛋白A/C（LMNA）基因突变。LMNA编码核纤层的主要蛋白，核纤层是与细胞核和细胞骨架相互作用的核膜的结构基质。在这项提案中，我们将测试LMNA突变与多个长度尺度的结构，组织和功能缺陷相关的假设。在家庭之间，缺陷的严重程度与LMNA突变的类型相关;在家庭内部，严重程度被其他遗传因素改变。我们的长期目标是直接从患者中开发体外疾病模型，以了解突变和遗传修饰剂如何影响适当的细胞结构，组织结构和收缩功能。在具体目标1中，我们将使用外显子组测序和体外组织工程技术来评估LMNA患者和对照组成纤维细胞中细胞和核形态、细胞内结构、运动性和组织自组装和结构的基因组变异和缺陷。在具体目标2中，我们将从成纤维细胞中获得诱导多能干细胞（iPS），并分析来自LMNA患者和对照组的iPS衍生心肌细胞的细胞结构和组织结构。在具体目标3中，我们将使用RNA测序来测试改变的基因表达，并使用“芯片上的心脏”来表征来自LMNA患者和对照组的iPS衍生的心肌细胞的收缩功能（频率，收缩，舒张和抽搐应力）。这些结果结合遗传和表型变异的信息将暗示我们将进一步研究的途径和功能。了解基因型和紧急表型之间的复杂关系，并确定修饰因子将提供深入了解心脏病的机制，并可能有助于开发新的预防，诊断和治疗策略。

 DESCRIPTION (provided by applicant): Cardiomyopathies and arrhythmia are conditions with high morbidity and limited therapies. Although a vast number of genes have been discovered to contribute to the etiology of these diseases, translational research- the practical application of genetic knowledge to improve screening, diagnosis, and treatment for affected individuals and their families-has been limited. One major obstacle is the lack of functional studies to understand the relationship between genotype and emergent phenotype at multiple physiological scales (cells to tissues) and to identify factors that cause clinical variability between and within families. The proposed study focuses on three affected families each with different mutation in the Lamin A/C (LMNA) gene. LMNA encodes the main protein of the nuclear lamina, the structural matrix of the nuclear envelope that interacts with both the cell nucleus and cytoskeleton. In this proposal, we will test the hypothesis that LMNA mutations are associated with defects in the structure, organization, and function at multiple length-scales. Between families, the severity of the defects is associated with the type of LMNA mutation; and within families, severity is modified by additional genetic factors. Our long term goals are to develop in vitro disease models directly from patients to understand how proper cell structure, tissue organization, and contractile function are affected by the mutation and genetic modifiers. In Specific Aim 1, we will use exome sequencing and in vitro tissue engineering techniques to evaluate genomic variation and defects in cell and nuclear morphology, intracellular architecture, motility, and tissue self-assembly and architecture in fibroblasts from LMNA patients and controls. In Specific Aim 2, we will derive induced pluripotent stem cells (iPS) from fibroblasts and analyze cell structure and tissue organization of iPS-derived cardiomyocytes from LMNA patients and controls. In Specific Aim 3, we will use RNA sequencing to test for altered gene expression and the "Heart-on-a-Chip" to characterize contractility function (frequency, systolic, diastolic, and twitch stresses) of iPS-derived cardiomyocytes from LMNA patients and controls. These results combined with information of genetic and phenotypic variances will imply pathways and functionalities we will further study. Understanding of the complex relationship between genotype and emergent phenotype and identifying modifying factors will provide insight into the mechanism of heart disease and may assist in the development of new preventative, diagnostic, and therapeutic strategies.